Cell therapy company reports net loss of $.04 per share for first quarter.

2003 JUN 9 - (NewsRx.com & NewsRx.net) -- Aastrom Biosciences, Inc., (ASTM) announced financial results and operational progress for the third quarter ended March 31, 2003.

Quarterly highlights included several significant business milestones. The company announced in early January 2003 two marketing agreements, in Italy and in Turkey, that will expand the sales and marketing of its Cell Production Products (CPP) product line to those countries. Both relationships provide support for the sales and distribution of the company's CE-Marked AastromReplicell System, and associated CE-Marked cell production kits for the ex vivo production of dendritic cells for cell-based cancer vaccines.

In addition, in March 2003 Aastrom announced that it had signed a 3-year master supply agreement with Astro Instrumentation, …